IDH1 and acute myeloid leukemia: Since May 2023, the European Medicines Agency (EMA) has approved Ivosidenib for the treatment of newly diagnosed adult AML patients harboring IDH1 R132 mutations but deemed medically unfit for IC, both in combination with azacitidine or alone in patients >75 years old or with comorbidities.